FRG Family Wealth Advisors LLC Cuts Stock Position in Becton, Dickinson and Company $BDX

FRG Family Wealth Advisors LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 2.0% in the second quarter, Holdings Channel.com reports. The firm owned 13,777 shares of the medical instruments supplier’s stock after selling 275 shares during the quarter. FRG Family Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,373,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BDX. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $27,000. Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $31,000. Finally, Bank of Jackson Hole Trust lifted its stake in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 1,895 shares of company stock worth $358,995. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BDX shares. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Trading Down 1.5%

BDX opened at $181.49 on Thursday. The business has a 50 day simple moving average of $189.14 and a two-hundred day simple moving average of $183.39. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 32.64, a PEG ratio of 1.44 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.